A

AARD

AARD

UnknownUnknown

Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.

Insider Sentiment
Based on recent trading activity
56%Neutral
Buy/Sell Ratio98% buys
BearishBullish
AARD Live QuoteReal-time
$0.91
$2.99(-76.67%)1M
Day Range$0.91 – $1.21
Open$1.16
Previous Close$1.15
Volume530.0K
Key Financials & Valuation
Fundamental balance sheet & market metrics
HEALTHCARE
Market Cap$19.92M
P/E Ratio (TTM)24.5
Forward P/ENaN
EPS (TTM)$-3.33
Price to Book0.4
Dividend Yield0.65%
Beta (Volatility)1.18
IndustryBIOTECHNOLOGY
52-Week RangeCurrent: $0.91 (0%)
Low: $0.91High: $16.60
Wall Street Consensus
Sell
Analyst Rating
2.2/ 5.0
Target Price
$4.00-97.3% upside

Insider Buys

9

$23.87M

Insider Sales

1

$395K

Total Volume

$24.27M

16 transactions

Net Activity

+$23.48M

Net buying

Proprietary Ratings
Calculated from Form 4 transactions
100CONFIDENCE

Sentiment Rating

Strong Accumulation

CEO Conviction Index

High Conviction Accumulation

Key Drivers

  • •Strong buying bias: purchases represent 98% of total transaction value.
  • •Cluster buying: 4 unique insiders purchased shares, showing strong alignment.
  • •CEO buying activity detected. When chief executives put their own money at risk, it is historically a strong bullish signal.
  • •CFO buying activity detected. Statistical studies show CFO purchases have high predictive power due to their direct visibility into balance sheet details.
  • •Ultra-high accumulation: total purchase value exceeds $10M.
Score Methodology

The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:

  • +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
  • +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
  • +15CEO Buying: CEO committing own capital shows high conviction.
  • +10CFO Buying: CFO purchasing shares shows financial alignment.
Top Insiders
Most active traders
M
1

Multiple Insiders

S - Sale Insiders

0 buys6 sells

$4987.90B total

D
2

Decheng Capital Global Life Sciences Fund Iv, L.P.

10%

1 buys0 sells

$20.00M total

C
3

Cormorant Asset Management, LP

Former 10% Owner

1 buys0 sells

$3.00M total

S
4

Sun Nelson

See Remarks

3 buys1 sells

$647K total

L
5

Lee Tien-Li

CEO, 10%

4 buys0 sells

$623K total

Trading History
AARD insider transactions from SEC Form 4 filings
DateInsiderTypeSharesPriceValueFiling

Sep 10, 2026

2 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell35.5K$-76754.00$0

Sep 10, 2026

2 months ago

Sun Nelson

See Remarks

Insider
Sell76.8K$5.15$395K

Dec 11, 2025

11 months ago

Lee Tien-Li

CEO, 10%

CEO
Buy7.0K$14.49$101K

Dec 11, 2025

11 months ago

Multiple Insiders

P - Purchase Insiders

Insider
Sell108.5K$3000.00$325.45M

Dec 11, 2025

11 months ago

Sun Nelson

CFO

CFO
Buy3.0K$14.40$43K

Sep 15, 2025

14 months ago

Lee Tien-Li

CEO, 10%

CEO
Buy10.0K$9.66$97K

Sep 15, 2025

14 months ago

Multiple Insiders

P - Purchase Insiders

Insider
Sell3.02M$10000.00$30.17B

Sep 10, 2025

14 months ago

Multiple Insiders

P - Purchase Insiders

Insider
Sell3.01M$20000.00$60.15B

Sep 10, 2025

14 months ago

Lee Tien-Li

CEO, 10%

CEO
Buy20.0K$8.03$161K

Sep 9, 2025

14 months ago

Multiple Insiders

P - Purchase Insiders

Insider
Sell105.5K$6000.00$632.90M

Sep 9, 2025

14 months ago

Sun Nelson

CFO

CFO
Buy6.0K$8.07$48K

Feb 14, 2025

21 months ago

Multiple Insiders

P - Purchase Insiders

Insider
Sell3.92M$1250000.00$4896.62B

Feb 14, 2025

21 months ago

Decheng Capital Global Life Sciences Fund Iv, L.P.

10%

10% Owner
Buy1.25M$16.00$20.00M

Feb 14, 2025

21 months ago

Lee Tien-Li

CEO, 10%

CEO
Buy16.5K$16.00$265K

Feb 14, 2025

21 months ago

Sun Nelson

CFO

CFO
Buy10.0K$16.00$160K

Feb 14, 2025

21 months ago

Cormorant Asset Management, LP

Former 10% Owner

10% Owner
Buy187.5K$16.00$3.00M
Sector & Industry Benchmarks
Unknown Comparison Overview
Industry Buy Conviction6%
AARD Buy Conviction98%
Industry Rank#0 of 563
Volume Contribution0.1%
Total Industry Activity$16.73B

AARD has an insider buy conviction of 98%, compared to the Unknown sector buy average of 6%.

Insider Trading Summary & Commentary
Automated executive transaction analysis for AARD

Over the last 90 days, corporate insiders at AARD (AARD) engaged in a total of 16 transactions reported via SEC Form 4 filings. Among these, 9 were open-market purchases and 1 were sales. The total volume of insider trading reached $24.27M.

The net insider activity for AARD shows a net buying bias of $23.48M. This activity represents a 98% buy ratio, suggesting that insiders are currently strongly bullish on the company's near-term outlook relative to recent history.

The most notable individual transaction was a Sale by Multiple Insiders (P - Purchase Insiders), who traded 3.92M shares valued at $4896.62B on Feb 14, 2025.

Live Market News & Developments
Aggregated real-time headlines for AARD (AARD)
6 updates

AARD Stock News: Robbins LLP Reminds Aardvark Therapeutics, Inc. Stockholders to Contact the Firm Before the October 13, 2026 Lead Plaintiff Deadline

Morningstar50d ago

AARD - Aardvark Therapeutics Inc Stock Price and Quote

Finviz176d ago

Why Is Aardvark Therapeutics Stock Trading Lower Today? - Aardvark Therapeutics (NASDAQ:AARD)

Benzinga27d ago

AARD Stock Price and Chart — NASDAQ:AARD

TradingView216d ago

AARD Stock Slides As FDA Hold And Class Actions Mount

StocksToTrade27d ago

Aardvark Therapeutics (AARD) Stock Forum and Discussion

Moomoo124d ago

FAQs About AARD Insider Trading

Answers to common questions regarding corporate filings and executive sentiment for AARD.

Based on SEC Form 4 disclosures, the Insider Confidence Score for AARD is currently 100/100, which reflects a strong accumulation bias. This calculation accounts for a total of 9 purchases and 1 sales by company executives over the last 90 days.

The CEO Conviction Index for AARD is rated as "High Conviction Accumulation". Executive buying is typically a strong vote of confidence as C-level leaders have the most intimate knowledge of their firm's prospects. Officer selling, on the other hand, is often routine and does not automatically signal operational weakness.

No. Insider tracking is a highly informative technical signal that indicates executive sentiment, but it should not be the sole basis for a transaction. Investors should combine this filing analysis with company financials, sector trends, and risk management criteria.